This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
TCRR 주식 개요
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.
TCR2 Therapeutics Inc. 경쟁사
가격 내역 및 성능
| 과거 주가 | |
|---|---|
| 현재 주가 | US$1.48 |
| 52주 최고치 | US$3.88 |
| 52주 최저치 | US$0.82 |
| 베타 | 1.93 |
| 11개월 변경 | -21.28% |
| 3개월 변경 사항 | 22.31% |
| 1년 변경 사항 | -38.59% |
| 33년 변화 | -88.47% |
| 5년 변화 | n/a |
| IPO 이후 변화 | -90.18% |
최근 뉴스 및 업데이트
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10주주 수익률
| TCRR | US Biotechs | US 마켓 | |
|---|---|---|---|
| 7D | -6.3% | -1.6% | -0.06% |
| 1Y | -38.6% | 10.4% | 20.5% |
수익률 대 산업: TCRR underperformed the US Biotechs industry which returned 12.2% over the past year.
수익률 대 시장: TCRR underperformed the US Market which returned 2.4% over the past year.
가격 변동성
| TCRR volatility | |
|---|---|
| TCRR Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
안정적인 주가: TCRR's share price has been volatile over the past 3 months.
시간에 따른 변동성: TCRR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
회사 소개
| 설립 | 직원 | CEO | 웹사이트 |
|---|---|---|---|
| 2015 | 58 | Garry Menzel | www.tcr2.com |
TCR2 Therapeutics Inc. 기본 사항 요약
| TCRR 기본 통계 | |
|---|---|
| 시가총액 | US$58.11m |
| 수익(TTM) | -US$163.10m |
| 수익(TTM) | n/a |
0.0x
P/S 비율-0.4x
P/E 비율TCRR 주가가 과대평가되어 있나요?
공정 가치 및 가치 분석 보기수익 및 수익
| TCRR 손익 계산서(TTM) | |
|---|---|
| 수익 | US$0 |
| 수익 비용 | US$0 |
| 총 이익 | US$0 |
| 기타 비용 | US$163.10m |
| 수익 | -US$163.10m |
최근 보고된 수익
Mar 31, 2023
다음 수익 날짜
n/a
| 주당 순이익(EPS) | -4.15 |
| 총 마진 | 0.00% |
| 순이익 마진 | 0.00% |
| 부채/자본 비율 | 0% |
TCRR 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기